Clinical Test Expectation – Peptide-T – Human Subjects : HIV Inhibitor. Strong antiviral. Anti-Inflammatory action. Treating neuro-aids and neurodegenerative diseases such as Parkinson’s Disease
Strength – 50mg per vial
Peptide T, and its modified analog Dala1-peptide T-amide (DAPTA), a drug in clinical trials, is a short peptide derived from the HIV envelope protein gp120 which blocks binding and infection of viral strains which use the CCR5 receptor to infect cells.
Peptide T has several positive effects related to HIV disease and Neuro-AIDS. A FDG-PET neuro-imaging study in an individual with AIDS dementia who completed a 12-wk treatment with intranasal DAPTA, showed remission in 34 out of 35 brain regions after treatment. A placebo-controlled, three site, 200+ patient NIH-funded clinical trial, which focused on neurocognitive improvements, was conducted between 1990 and 1995. The results showed that DAPTA was not significantly different from placebo on the study primary end points. However, 2 of 7 domains, abstract thinking and speed of information processing, did show improvement in the DAPTA group (p<.05). Furthermore, twice as many DAPTA-treated patients improved, whereas twice as many placebo patients deteriorated (P=.02). A sub-group analysis showed that DAPTA had a treatment effect and improved global cognitive performance (P=.02) in the patients who had more severe cognitive impairment.
An analysis of antiviral effects from the 1996 NIH study showed peripheral viral load (combined plasma and serum) was significantly reduced in the DAPTA-treated group. An eleven-person study for peptide T effects on cellular viral load showed reductions in the persistently infected reservoir to undetectable levels in most of the patients. Elimination of viral reservoirs, such as the persistently infected monocytes or brain microglia, is an important treatment goal.
Peptide T clinical development was stopped due to the propensity of the liquid nasal spray to lose potency upon storage and shifted to its shorter oral analog, the pentapeptide CCR2/CCR5 antagonist RAP-103 (Receptor Active Peptide) for neuropathic pain and neurodegeneration. RAP-103 also blocks CCR8, which may be important in neuropathic pain. Inhibitors of CCR5, including DAPTA, prevent and reverse neurodegeneration and are therapeutic targets in stroke/brain injury and dementia, such as in Parkinsons Disease
You inject 2ml water into the vial of Peptide-T from the water vial. 1 full syringe is 1ml. You then wait for the vial powder content to dissolve ON ITS OWN. DO NOT SHAKE THE VIAL TO MIX POWDER. Once dissolved and clear in colour you draw out 20 (2 units) on the syringe each morning before breakfast and inject it into the tummy under the skin into the fatty skin layer.
How long will a vial last ?
A vial should last 10 days.
Whatsapp our support team now for help with this item or others ! Click HERE to connect with us !